Irish Medicines Database — 10,165 HPRA-Authorised Products

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

84 results for “Baxter”

Medicine	Active substance	Licence holder	Status
Aciclovir 25mg/ml Concentrate for solution for infusion PA2299/041/001	Aciclovir	Baxter Holding B.V.	Not marketed
ARTISS Solutions for Sealant, deep frozen PA2299/026/001	Human fibrinogen, Human thrombin, Calcium chloride, Aprotinin	Baxter Holding B.V.	Marketed
Brevibloc Premixed 10 mg/ml solution for Infusion PA2299/021/002	Esmolol Hydrochloride	Baxter Holding B.V.	Marketed
Brevibloc Premixed 10 mg/ml Solution for Injection PA2299/021/001	Esmolol Hydrochloride	Baxter Holding B.V.	Marketed
Bupivacaine 2.5 mg/ml Solution for Injection PA2299/035/001	Bupivacaine hydrochloride, monohydrate	Baxter Holding B.V.	Not marketed
Bupivacaine 5 mg/ml Solution for Injection PA2299/035/002	Bupivacaine hydrochloride, monohydrate	Baxter Holding B.V.	Marketed
Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion EU/1/96/011/001-004	DOXORUBICIN HYDROCHLORIDE	Baxter Holding B.V.	—
Ceprotin EU/1/01/190/001	Protein c	Baxter Vaccine AG	—
Ceprotin EU/1/01/190/002	Protein c	Baxter Vaccine AG	—
Cernevit, Powder for Solution for Injection or Infusion PA2299/019/001	Retinol palmitate, Cholecalciferol, Dl-a-tocopherol, Ascorbic acid, Cocarboxylase tetrahydrate	Baxter Holding B.V.	Marketed
Chlorhexidine acetate 0.015% w/v and Cetrimide 0.15% w/v Irrigation solution PA2299/005/001	Chlorhexidine acetate, Cetrimide	Baxter Holding B.V.	Not marketed
Chlorhexidine Acetate BP 0.05% w/v Irrigation solution PA2299/004/001	Chlorhexidine acetate	Baxter Holding B.V.	Marketed
CLINIMIX N14G30E, solution for infusion PA2299/020/001	L-leucine, L-phenylalanine, L-methionine, L-isoleucine, L-valine	Baxter Holding B.V.	Marketed
Compound Sodium Lactate Solution for Infusion BP PA2299/012/001	Sodium chloride, Potassium chloride, Calcium chloride dihydrate, Sodium lactate	Baxter Holding B.V.	Marketed
Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion PA2299/050/001	Dexmedetomidine hydrochloride	Baxter Holding B.V.	Not marketed
Endoxana Coated Tablets 50 mg PA2299/027/003	Cyclophosphamide monohydrate	Baxter Holding B.V.	Marketed
Endoxana Injection 1000 mg Powder for Solution for Injection PA2299/027/002	Cyclophosphamide	Baxter Holding B.V.	Marketed
Endoxana Injection 500 mg Powder for Solution for Injection PA2299/027/001	Cyclophosphamide	Baxter Holding B.V.	Marketed
Eribulin Baxter 0.44 mg/mL solution for injection EU/1/24/1819/001	Eribulin mesylate	Baxter Holding B.V.	—
Finomel Emulsion for Infusion PA2299/044/002	Glycine, Alanine, Arginine, Histidine, Isoleucine	Baxter Holding B.V.	Marketed
Finomel Peri Emulsion for Infusion PA2299/044/001	Alanine, Arginine, Glycine, Histidine, Isoleucine	Baxter Holding B.V.	Marketed
Fluconazole 2 mg/ml solution for infusion PA2299/033/001	Fluconazole	Baxter Holding B.V.	Marketed
Furosemide 10 mg/ml Solution for Injection PA2299/036/001	Furosemide	Baxter Holding B.V.	Not marketed
Glucose 10% w/v Solution for Infusion PA2299/003/002	Glucose	Baxter Holding B.V.	Marketed
Glucose 5% w/v Intravenous Infusion BP, polyolefin/polyamide bag PA2299/003/001	Glucose	Baxter Holding B.V.	Marketed
Heparin Sodium BP 1000 IU/l in 0.9% w/v Sodium Chloride IV Infusion PA2299/014/001	Heparin sodium, Sodium chloride, Disodium phosphate dodecahydrate, Citric acid monohydrate	Baxter Holding B.V.	Marketed
Heparin Sodium BP 2000 IU/l in 0.9 % w/v Sodium Chloride IV infusion PA2299/014/002	Citric acid monohydrate, Disodium phosphate dodecahydrate, Sodium chloride, Heparin sodium	Baxter Holding B.V.	Marketed
Kiovig 100 mg/ml solution for infusion EU/1/05/329/001-006	Human normal immunoglobulin	Baxter AG	—
Maintelyte solution for infusion PA2299/045/001	Sodium chloride, GLUCOSE MONOHYDRATE PH. EUR., Sodium acetate, trihydrate, POTASSIUM CHLORIDE PH. EUR., MAGNESIUM CHLORIDE HEXAHYDRATE PH. EUR.	Baxter Holding B.V.	Marketed
Mannitol 10% Solution for Infusion BP PA2299/006/001	Mannitol	Baxter Holding B.V.	Marketed
Mannitol 15% w/v solution for infusion PA2299/006/002	Mannitol	Baxter Holding B.V.	Marketed
Mitoxana 1 g Powder for Sterile Concentrate PA2299/028/001	Ifosfamide	Baxter Holding B.V.	Marketed
Mitoxana 2 g Powder for Sterile Concentrate PA2299/028/002	Ifosfamide	Baxter Holding B.V.	Marketed
Numeta G13%E Preterm emulsion for infusion PA2299/030/003	Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid	Baxter Holding B.V.	Marketed
Numeta G16%E emulsion for infusion PA2299/030/001	Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid	Baxter Holding B.V.	Marketed
Numeta G19%E emulsion for infusion PA2299/030/002	Methionine, Ornithine hydrochloride, Phenylalanine, Proline, Serine	Baxter Holding B.V.	Marketed
OBIZUR 500 U powder and solvent for solution for injection EU/1/15/1035/001-003	Susoctocog alfa	Baxter Innovations GmbH	—
Ondansetron 2mg/ml Solution for Injection PA2299/037/001	Ondansetron	Baxter Holding B.V.	Marketed
Paracetamol 10 mg/ml solution for infusion PA2299/049/001	Paracetamol	Baxter Holding B.V.	Not marketed
Pemetrexed Baxter 100 mg powder for concentrate for solution for infusion EU/1/22/1705/001	Pemetrexed disodium heptahydrate	Baxter Holding B.V.	—
Pemetrexed Baxter 500 mg powder for concentrate for solution for infusion EU/1/22/1705/002	Pemetrexed disodium heptahydrate	Baxter Holding B.V.	—
Plasma-Lyte 148 & Glucose 5% w/v solution for infusion PA2299/007/001	Glucose monohydrate, Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate	Baxter Holding B.V.	Marketed
Plasma-Lyte 148 (pH 7.4) solution for infusion PA2299/032/001	Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate, Sodium gluconate	Baxter Holding B.V.	Marketed
Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion - BP PA2299/010/002	Potassium chloride, Sodium chloride	Baxter Holding B.V.	Marketed
Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/002	Potassium chloride, Glucose	Baxter Holding B.V.	Marketed
Potassium Chloride 0.15% w/v, Sodium Chloride 0.18% w/v, Glucose 4% w/v Solution for Infusion PA2299/001/002	Potassium chloride, Sodium chloride, Glucose anhydrous	Baxter Holding B.V.	Marketed
Potassium Chloride 0.3 % w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/001	Potassium chloride, Glucose (as monohydrate)	Baxter Holding B.V.	Marketed
Potassium Chloride 0.3% w/v & Sodium Chloride 0.9% w/v Solution for Infusion BP PA2299/010/001	Potassium chloride, Sodium chloride	Baxter Holding B.V.	Marketed
Potassium Chloride 0.3% w/v and Sodium Chloride 0.18% w/v in Glucose 4% w/v Intravenous Infusion BP (Viaflo Container) PA2299/001/001	Potassium chloride, Sodium chloride, Glucose monohydrate	Baxter Holding B.V.	Marketed
Primene 10% Solution for Infusion PA2299/018/001	L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine	Baxter Holding B.V.	Marketed

1 2 →

Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 12 August 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.